Dr. Hind Medyouf, a group leader at the Institute for Tumor Biology and Experimental Therapy and member of the µBone consortium, has been awarded the prestigious European Molecular Biology Organization (EMBO) Young Investigator Programme (YIP) for the years 2019-2022. She joins an active network of 102 current and 314 past Young Investigators. http://www.embo.org/news/press-releases/2018/embo-welcomes-twenty-six-new-young-investigators
The EMBO Young Investigator Programme will facilitate and further promote Dr. Medyouf’s collaborations with colleagues within and outside the EMBO community, which will help to achieve her research goals. “I am thrilled and honored to join such a distinguished programme. The EMBO YIP brings together outstanding young scientists and helps them in their career by providing mentorship, increased visibility, facilitating travel to meetings, promoting collaborations as well as providing access to EMBL facilities. This is extremely attractive, as my lab members can also take advantage of many of these benefits. The program simply offers great opportunities for our group”, Dr. Medyouf said about the EMBO award.
About Hind Medyouf
Dr. Medyouf joined the Institute for Tumor Biology and Experimental Therapy in October 2014, after postdoctoral training at the Terry Fox Laboratory in Canada and the German Cancer Centre. Her current research is focused on exploring the role of the tumor microenvironment in leukemia and solid cancer metastasis. Besides the µBone consortium, Dr. Medyouf’s research program is currently supported by the European Research Council (ERC Starting grant), the German José Carreras Leukemia Foundation (DJCS), the German Cancer Consortium (DKTK) as well as the Frankfurt Cancer Institute (FCI).